VENTAC PARTNERS IS A DEDICATED LIFE SCIENCE CONSULTING FIRM WITH OFFICES IN EUROPE, USA AND ASIA.

Ventac Partners has a strong track record in founding new innovative companies, strategic and operational market and product analysis, intellectual property development, fund raising, licensing, M&A and strategy consulting.

All partners are experienced executives from pharma, biotech and medtech companies, and preclinical, clinical and regulatory, legal and intellectual property experts with extensive backgrounds in successfully starting, growing and expanding international life science companies.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Latest News
May, 2014 | Ventac Partners organizes a biotech entrepreneurship  course at the Asia BioInvest 2014 conference in Hong Kong (June 3).

April, 2014 | RhoVac Aps and Ventac Partners enter in agreement to develop therapeutic vaccines based on RhoC peptides towards first-in-man clinical trials, see Portfolio News.

April, 2014 | VP and the Norwegian University of Science and Technology successfully complete 12th annual course on Patenting and Commercializing Biotech and Medtech Inventions, see VP News.

November, 2013 | Avexxin AS has completed an additional series B round financing facilitated by Sparebank1 SMN Markets, Norway, see Portfolio News.

 

Newsblitz

Avexxin

Avexxin announces positive results from its clinical phase I/IIa trial with AVX001 in sixty eight patients suffering from mild-to-moderate psoriasis.

For more information, see Portfolio News